President & CEO Sean Saint sells $322,380 in Beta Bionics stock

Sean Saint, President and CEO of Beta Bionics Inc., sold 16,867 shares of the company's stock on September 2, 2026. The sale took place at a weighted average price of $19.1131 per share, amounting to a total of approximately $322,380. Currently, each share of Beta Bionics stock is trading at $19.92, indicating a substantial 72% return over the past six months, according to InvestingPro data.

However, Beta Bionics' Fair Value analysis suggests the stock may be overpriced at its current level. This transaction was conducted to satisfy tax withholding requirements pertaining to the vesting of restricted stock units that Saint received. Following the sale, Saint now directly owns 404,070 shares of Beta Bionics common stock.

In addition to his role as President and CEO, Saint also serves on the company's board of directors. InvestingPro provides 7 further exclusive tips regarding BBNX, encompassing insights into the company's financial health and profit outlook. Recently, Beta Bionics disclosed a larger-than-anticipated loss for the second quarter of 2026, although the company's revenue expanded by 38%.

The company reported a loss of 53 cents per share, surpassing the projected loss of 34 cents per share. Despite the earnings disappointment, the company's revenue rose to $32 million, and the company bolstered its gross margin while reaffirming its full-year guidance. Furthermore, William Blair commenced coverage of Beta Bionics with a Market Perform rating.

Analyst Steven Lichtman lauded the company's distinctive AID algorithm utilized in the iLet insulin pump, which demands significantly less patient involvement, as a favorable factor. These developments outline Beta Bionics' continuous endeavors to refine its technology and financial performance.